How will recent agency initiatives and likely future directions for regulatory CMC guidance impact the cellular immunotherapy space?

Cell & Gene Therapy Insights 2024; 10(7), 661–670

DOI: 10.18609/cgti.2024.079

Published: 6 June
Adeyemi Afuwape

It has been a busy past year or two in terms of regulatory evolution and initiatives that impact cellular immunotherapy developers. David McCall, Senior Editor, BioInsights, invites Adeyemi Afuwape to unpack some key pieces of recent guidance on the regulatory CMC side, and to share his thoughts on what the future may hold in this regard.